Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Verrica Pharmaceuticals Inc. reported revenue of $36M, up 370.2% year over year. Operating margin was -34.2% and net margin -50.3%, on a free-cash-flow margin of -49.5% with capital expenditure at 0.0% of revenue. Every figure is computed directly from VRCA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $36M | -34.2% | -50.3% |
| FY2024 | $8M | -871.3% | -1012.1% |
| FY2023 | $5M | -1283.4% | -1307.5% |
| FY2022 | $9M | -235.8% | -271.1% |
| FY2021 | $12M | -257.6% | -292.3% |
How does VRCA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.